Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that sales of combination drug therapies for type 2 diabetes, such as GlaxoSmithKline's metformin/rosiglitazone and Bristol-Myers Squibb's metformin/glipizide and metformin/glyburide will increase at a vigorous annual rate of 24%, capturing 16% of the type 2 diabetes market in 2011. This growth rate will bring sales of combination drug therapies in the major pharmaceutical markets (the United states, France, Spain, Italy, Germany, United Kingdom, and Japan) for type 2 diabetes from $335 million in 2001 to nearly $2.9 billion in 2011, according to a new Pharmacor report entitled Type 2 Diabetes. The report also forecasts that PPAR-gammas will add significantly to the market, with a growth rate of 10.6% per year, bringing sales of this class from $1.9 billion in 2001 to $3.1 billion in 2006.

(Photo: )

"The type 2 diabetes market will double to $17.2 billion in 2011, reflecting sustained, robust annual growth of 7% from 2001 through 2011," said Carole deDios, analyst at Decision Resources. "Much of this growth will be from single-pill combinations, which improve ease of dosing, and from PPAR- gammas, which will become even more popular with physicians as they increasingly learn how to manage patients with these agents."

Disease Background-Type 2 Diabetes

Type 2 diabetes is a progressive disease of metabolic dysregulation characterized by insulin resistance and impaired insulin secretion. Prolonged lack of control over glucose levels often results in debilitating complications. The International Diabetes Foundation recently warned that type 2 diabetes has become a global pandemic and one of the most challenging public health problems of the 21st century. Because of the chronic and insidious nature of the disease after onset, patients' quality of life is severely affected, and the medical costs can be substantial.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Type 2 Diabetes is Metabolic Disorders report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.,

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Structural Proteomics will Accelerate Drug Discovery and Reduce Its Cost, but Advances in Automation and Information Technology Are Required for Full Development and Exploitation

View Now